The US firm has two assets but the future looks less than rosy for one of them, the lung cancer therapy poziotinib, after the drug failed a Phase II study.
Shares in Spectrum Pharmaceuticals Inc. have taken a battering on the news that the US firm's investigational lung cancer drug poziotinib failed to meet its main goal in a mid-stage clinical trial.
The Nevada-headquartered group reported that the primary endpoint in its Phase II trial called Zenith20 evaluating poziotinib in previously treated...
Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.
Multi-blockbuster falls short in a giant cell arteritis study.
